Puma Biotechnology Inc - Common Stock (PBYI)

NERLYNX demand surged 12% year over year as Puma raised full-year guidance.

Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $

Puma (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company’s earnings call. Management attributed the quarter’s product revenue

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Puma Biotech (PBYI) Earnings Call Transcript

Puma Biotech's Q3 2025 earnings beat expectations, driven by strong NERLYNX sales. The company raised its full-year revenue guidance and advances its clinical pipeline.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.